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Fibrinogen (Fbg) mediates platelet aggregation by
binding the aIIbb3 integrin receptor, but the interac-
tion of the receptor with peptide motifs of Fbg re-
mains unresolved. This paper describes the use of
self-assembled monolayers (SAMs) to study the
adhesion of aIIbb3-transfected CHO cells to the
GRGDS and HHLGGAKQAGDV motifs within Fbg.
Cells adhered to and spread on monolayers present-
ing either peptide. Cell adhesion could be inhibited
by either soluble peptide, demonstrating that the
peptides bind competitively to the integrin. A peptide
array was used to show that AGD was the minimal
binding sequence in HHLGGAKQAGDV and that the
receptor recognizes ligands of the form GXGDSC,
where X is a hydrophobic or basic residue. This
work revises our understanding of the aIIbb3 speci-
ficity and also suggests a new class of antithrom-
botic agents.
INTRODUCTION
Fibrinogen (Fbg) is an abundant plasma protein that is essential
for homeostasis. This protein is a disulfide-linked homodimeric
complex assembled from a, b, and g subunits and presents
multiple peptide motifs that bind the aIIbb3 integrin receptor
present on platelets and avb3 integrin on endothelial cells. In
this way, Fbg can aggregate platelets and localize the clot to
activated endothelium. Fbg also serves as an extracellular
matrix protein to mediate cell adhesion following its conversion
to insoluble fibrin by the protease thrombin (Bini et al., 2000).
Consequently, a substantial effort has been directed toward
identifying the binding sequences in Fbg that mediate platelet
aggregation and adhesion and understanding the differential
roles of these ligands. Previous work has implicated two
sequences for platelet aggregation—the RGD site on the a
subunit and a carboxy-terminal peptide on the g subunit—yet
the mechanistic roles of the two peptides remain controversial.
Here, we report a study that uses model substrates that present
defined peptide ligands to show that both the RGD and the
g-derived AGD sequences serve as competitive ligands for the
aIIbb3 receptor, and we show that the platelet receptor has
a relaxed specificity for its ligands and recognizes peptides
having a hydrophobic residue in the first position of the canonical
RGD motif.990 Chemistry & Biology 16, 990–1000, September 25, 2009 ª2009Fbg contains two peptide motifs that are important to its ability
to aggregate platelet receptors: an RGD sequence at position
572–574 on the Aa chain and a HHLGGAKQAGDV sequence
at position 400–411 of the g chain. There is a second RGD site
at position 95 in the Aa chain, but this ligand is likely conforma-
tionally masked within a coiled-coil domain and does not partic-
ipate in the initial aggregation of platelets (Doolittle et al., 1978;
Ugarova et al., 1993). A consensus has emerged that the RGD
sequence is important for binding to the avb3 receptor on endo-
thelial cells and thereby serves to localize a thrombus to regions
of activated endothelium. Furthermore, a series of studies has
established that the g peptide interacts with the platelet receptor
and is necessary for fibrinogen-mediated aggregation of plate-
lets (Hawiger et al., 1982; Kloczewiak et al., 1984; Farrell et al.,
1992). What has been less clear is whether the RGD motif is
also necessary in platelet aggregation and whether the g and
RGD peptides bind to common or separate sites on the receptor.
Bennett and co-workers reported studies that supported
a model wherein the two peptides bind to nonoverlapping sites
on the receptor. That study used two monoclonal antibodies to
probe the interaction of the receptor with the ligands: PAC-1,
which competes with Fbg in binding to aIIbb3, and A2A9, which
binds the integrin at a different site than does PAC-1 and steri-
cally blocks the binding of Fbg to the receptor. The peptide
RGDS blocked the binding of both PAC-1 and Fbg to platelets
with equal potency. The g-derived peptide LGGAKQAGDV also
inhibited Fbg binding to platelets with an affinity comparable to
that of RGDS but was 2.5-fold less potent in inhibiting PAC-1
binding to aIIbb3. Finally, LGGAKQAGDV, but not RGD, could
inhibit the binding of A2A9 to platelets. These results suggest
that the two peptides interact with the integrin at two different
sites (Bennett et al., 1988). Another cross-linking study of the
complex suggested that GRGDS interacts with the b3 subunit
(D’Souza et al., 1988), whereas HHLGGAKQAGDV interacts
with the heavy chain in the aIIb subunit, giving further evidence
in support of a two-binding-site model (D’Souza et al., 1990).
Further support for this model came from studies that used
surface plasmon resonance experiments to show that the two
binding sites in aIIbb3 are allosterically related (Hu et al., 1999)
and from a report that the peptides served two distinct functions,
with the initial cell adhesion mediated by HHLGGAKQAGDV and
subsequent cell spreading mediated by GRGDS (Salsmann
et al., 2005).
Other studies have supported a model wherein the two
peptides bind a common site on the platelet receptor. For
example, affinity chromatography experiments found that aIIbb3
bound to a resin presenting either RGD or g chain peptides and
could then be eluted with either peptide (Lam et al., 1987). AElsevier Ltd All rights reserved
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for the complex provides the strongest evidence that the two
peptides bind a common site. The structure reveals that the
HHLGGAKQAGDV peptide binds to an extended site on the
receptor that includes the RGD-binding site. Furthermore,
the structure revealed that the peptide adopts a conformation
that allows the lysine residue of the KQAGD sequence to interact
with the Arg-binding pocket on the receptor and was interpreted
to suggest that the minimal sequence for the ligand is KQAGD.
In this article, we use model substrates that present the
GRGDS and HHLGGAKQAGDV peptides—either alone or in
combination—to compare the activities of the ligands in an
adhesion assay of aIIbb3-transfected CHO K1 cells. These
biochemical findings are largely consistent with the recent struc-
tural data and support a common site for binding of the two
peptide motifs. Indeed, we find that both ligands mediate cell
adhesion and spreading through a common binding site on
aIIbb3. However, our results suggest that efficient cell adhesion
does not require the presence of the lysine residue in the peptide.
Rather, the peptide AGD retains the property of the full-length g
peptide in mediating cell adhesion and spreading. Furthermore,
we compared cell adhesion to a peptide array to show that the
platelet receptor recognizes peptides of the form XGD where X
is either a basic residue (R or K) or one of the hydrophobic resi-
dues (G, A, V, L, or I). Together with the recent structural report,
these adhesion experiments reveal the promiscuity of the
platelet receptor and identify the sequence determinants that
are important for active interaction with the platelet receptor.
RESULTS
Experimental Design
We used model substrates that mimic the extracellular matrix to
compare the roles played by the GRGDS and HHLGGAKQAGDV
sequences in Fbg for their ability to mediate the attachment and
spreading of cells in an aIIbb3 integrin-dependent manner. The
model substrates were self-assembled monolayers that pre-
sented the peptide ligands against a tri(ethylene glycol)-termi-
nated background (Mrksich, 2009). The use of monolayers
for studies of cell adhesion are notable because they allow the
identities, densities, and orientations of the peptides to be
controlled and, at the same time, are effective at preventing
the nonspecific adsorption of protein and, therefore, remodeling
of the matrix. The latter benefit owes to the terminal oligo(ethy-
lene glycol) groups on the monolayer. Several previous reports
have established the suitability of these model substrates for
mechanistic studies of cell adhesion (Kato and Mrksich, 2004;
Feng and Mrksich, 2004; Houseman et al., 2003; Murphy et al.,
2004).
We first prepared monolayers that presented a mixture of mal-
eimide groups and tri(ethylene glycol) groups, with the former
present at a density of 0.5% (relative to total alkanethiolate).
We treated the monolayers with cysteine-terminated peptides
to immobilize the ligands (Figure 1A). In each case, we used
mass spectrometry to verify immobilization of the peptides in
high yield (Su andMrksich, 2002). For example, amass spectrum
of monolayer to which the peptide GRGDSC was immobilized
showed the expected peaks for the sodium adducts of
symmetric glycol-substituted disulfide (m/z, 694.4) and theChemistry & Biology 16, 990–10mixed disulfide containing one glycol group and one GRGDSC
terminated alkanethiol (m/z, 1444.7) (Figure 1B). Similarly, a
mass spectrum of a monolayer to which the peptide HHLGGAK
QAGDVC had been immobilized displayed peaks for the sodium
adduct of the symmetrical glycol disulfide (m/z, 694.4) and the
mixed disulfide composed of one glycol group and one
HHLGGAKQAGDVC terminated alkanethiol (m/z, 2145.6) (Fig-
ure 1C). A SAMDI mass spectrum of the monolayer composed
of both peptides showed peaks corresponding to each
peptide-terminated disulfide and to the ethylene-glycol-termi-
nated disulfide. The peak corresponding to the GRGDSC disul-
fide was larger than that for the HHLGGAKQAGDVC disulfide,
likely owing to a higher ionization efficiency of the former. We
estimate that the relative density of the RGD peptide is between
0.35 and 0.65 in the monolayer.
We used CHO K1 cells that were transfected with the aIIbb3
receptor, as described elsewhere (Salsmann et al., 2005). Cells
were transfected with pcDNA3.1 vectors that coded for aIIb
and b3 using FuGENE6 and were analyzed by FACS after
labeling with the PAC-1 (anti-aIIbb3) and H-96 (anti-b3) anti-
bodies. Approximately 30% of the cells expressed the receptor
(Figure 2A). Because the CHO K1 cells also express av and a5
integrins on their surfaces, we performed adhesion experiments
in the presence of the cyclic peptide cRGDFG, where F is a D
amino acid. This peptide binds avb3 with an affinity that is
approximately 1,400-fold greater than that for the aIIbb3 integrin
(Haubner et al., 1996). We verified that this peptide, at a concen-
tration of 300 mM, could efficiently block the attachment of CHO
K1 cells to a monolayer presenting the GRGDSC peptide
(Figure 2D), but did not interfere with adhesion of aIIbb3 CHO
K1 cells to the same monolayer (Figure 2E). Treatment of trans-
fected cells with both the cyclic peptide inhibitor and the PAC-1
antibody, however, prevented cell adhesion to the monolayer
(Figure 2F). These results establish that the cRGDFG inhibitor
can be used to block av and a5 integrins on CHO cells and
therefore allow studies of aIIbb3-mediated adhesion of cells.
All experiments that follow, unless stated otherwise, were per-
formed in the presence of 300 mM cRGDFG.
Adhesion of aIIbb3 CHO K1 Cells to GRGDSC
and HHLGGAKQAGDVC
We compared the adhesion and spreading of aIIbb3 CHO K1
cells to monolayers presenting GRGDSC, HHLGGAKQAGDVC
and a mixture of both peptides. Cells were allowed to attach to
themonolayers in serum-free F-12 Kmedium for 2 hr, after which
themedia was exchanged with 10% FBS F-12Kmedium to facil-
itate cell spreading. We found that the cells adhered to mono-
layers presenting either the GRGDSC or the HHLGGAKQAGDVC
peptides with comparable efficiency, in both cases assuming
a flattened morphology with no refringent peripheral rim (Figures
3A–3C). The populations of cells on both substrates displayed
a similar morphology, suggesting that both peptides have suffi-
cient affinity for the receptor to support adhesion and spreading.
The mixed monolayer supported cell adhesion in a similar
manner as those that presented either peptide alone, suggesting
that GRGDSC and HHLGGAKQAGDVC do not have differential
roles in aIIbb3 mediated cell adhesion and spreading. As a posi-
tive control, we adsorbed Fbg to a hydrophobic monolayer and
observed a similar morphology for adherent cells (Figure 3D).00, September 25, 2009 ª2009 Elsevier Ltd All rights reserved 991
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(A) Self-assembled monolayer presenting a maleimide group among tri(ethylene glycol) background. The maleimide group allows for the covalent immobilization
of Cys-terminated peptides through a Michael addition. The glycol groups prevent nonspecific cell adhesion.
(B) SAMDI characterization of a 0.5% GRGDSC SAM. Tri(ethylene glycol) disulfide and GRGDSC-terminated mixed disulfide were detected. All were sodium
salts.
(C) SAMDI characterization of a 0.5% HHLGGAKQAGDVC SAM. Tri(ethylene glycol) disulfide and HHLGGAKQAGDVC-terminated mixed disulfide were
detected. All were sodium salts.Several additional control experiments showed that the adhe-
sion of cells on the model substrates was specific, including
a lack of cell attachment to monolayers that present only glycol
groups or unreacted maleimide groups (data not shown) and
a lack of cell attachment to monolayers that presented the
scrambled peptides GGRDGSC or GHHLGGADQAGKVC (data
not shown).992 Chemistry & Biology 16, 990–1000, September 25, 2009 ª2009Cytoskeletal Structure of Cells Adherent
to Model Substrates
We compared the assembly of focal adhesion and actin stress
fibers of aIIbb3 CHO K1 cells adhered to monolayers presenting
GRGDSC, HHLGGAKQAGDVC, a mixture of both peptides, and
adsorbed Fbg (Figures 3E–3H, respectively). We allowed aIIbb3
CHO K1 cells to attach and spread on the monolayers for 4 hrElsevier Ltd All rights reserved
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visualize focal adhesions, and with phalloidin-AF 488, to visu-
alize actin stress fibers. Nuclei were observed with DAPI. The
cells had well-developed cytoskeletal structures and mature
focal adhesions along the perimeter. Cells that were allowed to
adhere and spread on the three monolayers presenting the
peptide ligands showed comparable cytoskeletal structures,
demonstrating that the aIIbb3-mediated adhesion to either of
the peptide ligands is sufficient to support a well-formed cyto-
skeleton.
AGD is the Minimal Binding Motif for aIIbb3
We next compared the adhesion of cells to monolayers present-
ing several fragments taken from the HHLGGAKQAGDV
sequence in order to define theminimal bindingmotif. A compar-
ison of cell adhesion to monolayers presenting the three
Figure 2. aIIbb3 CHO K1 Cell Line
(A) CHO K1 cells do not express aIIbb3 (top). Transfected aIIbb3 CHO K1 cells
express aIIbb3 at the cell surface, as detected by anti-b3 and PAC-1 antibody
(bottom).
(B) cRGDFG, a cyclic peptide that specifically binds to a5 and aV integrins,
inhibits CHO K1 cell adhesion to 0.5% GRGDSC SAMs.
(C) CHO K1 cells adhere to 0.5% GRGDSC SAMs in the absence of inhibitors.
(D) CHO K1 cells fail to adhere to the same substrate in the presence of
[cRGDFG] = 300 mM.
(E) aIIbb3 CHO K1 cells adhere to 0.5% GRGDSC SAMs in the presence of
[cRGDFG] = 300 mM.
(F) This interaction is nulled by the presence of PAC-1.Chemistry & Biology 16, 990–1peptides HHLGGAC, KQAGDVC, and GGAKQAC—correspond-
ing to the first, last, and middle six residues in the sequence—
revealed that only the second sequence supported cell adhesion
(Figures 4A–4D). Further studies with monolayers presenting
N- and C-terminal truncations of this peptide revealed that the
AGD tripeptide supports efficient adhesion of cells (Figures
4E–4I). This result was surprising because the peptide has an
obvious relevance to the well-characterized RGD motif, yet
most integrins do not tolerate an Arg to Ala mutation in the ligand
and because previous work has identified sequences that
require the lysine residue.
GRGDS and AGDV Are Competitive Ligands for aIIbb3
To ask whether the two peptides interact with the same site on
aIIbb3, we determined whether the peptides GRGDS,
HHLGGAKQAGDV, and AGDV, in soluble form, could block the
attachment of cells to the monolayers presenting these ligands.
In these experiments, we first incubated identical suspensions of
cells (100,000/mL) in serum-free F-12K medium supplemented
with cRGDFG (300 mM) and with the soluble peptides in concen-
trations ranging from 1 pM to 100 mM and then applied the
mixtures to monolayers presenting either the GRGDSC,
HHLGGAKQAGDVC, or AGDVCpeptide (Figure 5). Cells were al-
lowed to attach for 2 hr, after which the media was exchanged to
10% FBS F-12K medium (supplemented with cRGDFG) and
cultured for an additional 2 hr. The slides were then rinsed, and
nuclei were stained with DAPI to facilitate counting of the
adherent cells. We first found that each peptide could block
the attachment of cells to monolayers presenting that peptide
in a concentration-dependent manner. This experiment again
verifies that the cell attachment is mediated by the immobilized
peptide alone and not nonspecific interactions between other
cell-surface molecules and the monolayer. We also found,
however, that each peptide could block cell attachment to
monolayers presenting any of the three peptides, demonstrating
that the ligands are, in fact, competitive in binding aIIbb3. The
soluble peptide HHLGGAKQAGDV, for example, blocked cell
attachment to a monolayer presenting GRGDS, as did the
soluble AGDV peptide. Control experiments confirmed that the
use of scrambled peptides GGRDGS, GHHLGGADQAGKV,
and GADGV as soluble inhibitors had no effect on cell adhesion.
Again, these results show that AGDV and GRGDS bind to the
aIIbb3 integrin competitively and suggest a common site on
the receptor.
Evaluating aIIbb3 Specificity with a Peptide Array
The aIIbb3 integrin, like other integrins, tolerates amino acid
substitutions on either side of the RGD sequence, but there
have been no suggestions that the receptors tolerate substitu-
tion of the arginine residue with a hydrophobic residue. The
report of the structure of the peptide-receptor complex, for
example, showed that the lysine residue within the g peptide
substitutes for the arginine residue but did not investigate a
peptide lacking the lysine residue and does not provide informa-
tion on the relative contribution of this interaction to the binding
affinity. To further probe the promiscuity of the aIIbb3 integrin for
RGDpeptide ligands, we used an array to assess the adhesion of
cells to peptides having the arginine residue substituted with
each amino acid other than cysteine. The library of Ac-GXGDSC000, September 25, 2009 ª2009 Elsevier Ltd All rights reserved 993
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peptide occupying a 1 mm diameter region of the monolayer
(Figure 6I). A suspension of aIIbb3 CHO K1 cells was applied
to the entire array, and cells were allowed to attach to regions
presenting the various peptides. The substrates were then rinsed
and stained with DAPI, and the cells were counted to determine
the relative efficiency of cell attachment to peptides in the library.
We found that the Arg residue could be substituted with the other
basic residue, Lys, or with hydrophobic residues (Figure 6A).
Substitution of the arginine residue with either glycine or alanine
gave ligands that were comparable to the parent sequence, and
substitutions with lysine and valine were only slightly less active.
Substitutions with leucine and isoleucine were also active,
Figure 3. aIIbb3 CHO Cell Adhesion and
Cytoskeletal Structure onModel Substrates
Optical micrographs of aIIbb3 CHO cells incu-
bated with [cRGDFG] = 300 mM that adhered and
spread on 0.5% SAMs presenting GRGDSC (A),
HHLGGAKQAGDVC (B), and a mixed monolayer
composed of both peptides (C). As a control,
aIIbb3 CHO cells adhered and spread on a dodec-
anethiol monolayer with adsorbed Fbg (D). Scale
bars are 300 mm. Immunofluorescence staining
of aIIbb3 CHO cells incubated with [cRGDFG] =
300 mM that adhered and spread on 0.5% SAMs
presenting GRGDSC (E), HHLGGAKQAGDVC (F),
a mixed monolayer composed of both peptides
(G) and the Fbg control (H). Focal adhesions
were visualized with an anti-vinculin antibody
(red), actin stress fibers were visualized with AF
488 phalloidin (green), and nuclei were visualized
with Hoescht (blue). Scale bars are 50 mm.
though at a lower level. Each of the other
substitutions gave peptides that failed to
support cell adhesion. aIIbb3 CHO K1
cells also failed to adhere to 0.5%
GGRDGSC, demonstrating the require-
ment for the GD scaffold for cell adhe-
sion. For the five most active peptides
from this array—those having Arg, Gly,
Ala, Lys, or Val at the first position—the
aIIbb3 CHO K1 cells had well-developed
actin structures with clear vinculin-con-
taining focal adhesions around the cell
perimeter (Figure 6).
We repeated this adhesion experiment
with CHO-K1, BHK 21, and HT1080 cells
and found that only Ac-GRGDSC
promoted significant cell adhesion, which
is consistent with the known specificity of
the a5 and av integrin receptors. These
cells also failed to adhere to 0.5%
GGRDGSC. Hence, these experiments
verify that the peptide arrays provide reli-
able information on the activity of pep-
tides for mediating cell adhesion and,
therefore, reveal that the aIIbb3 integrin
is less specific in its recognition of
peptide ligands and prefers ligands of the form XGD, where X
is either a basic or a hydrophobic residue.
DISCUSSION
The Peptides GRGDSC and AGDVC Mediate aIIbb3
CHO K1 Cell Adhesion
The most significant result from this work is the finding that the
platelet receptor can recognize the g carboxy-terminal se-
quence by primarily interacting with the AGDmotif. Furthermore,
AGD and RGD bind competitively to aIIbb3 and have a compa-
rable ability to mediate the adhesion of CHO cells engineered
with the receptor. Indeed, we found that aIIbb3 CHO K1 cells
994 Chemistry & Biology 16, 990–1000, September 25, 2009 ª2009 Elsevier Ltd All rights reserved
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aIIbb3 Binds to RGD and AGD Motifs in FibrinogenFigure 4. Truncation of HHLGGAKQAGDV Ligand to Find Minimal Binding Sequence
(A) Optical micrographs of aIIbb3 CHO K1 cells incubated with [cRGDFG] = 300 mM that adhered and spread on 0.5%KQAGDVC (D) but failed to adhere to 0.5%
HHLGGAC (B) and 0.5% GGAKQAC (C) SAMs. When KQAGDVC was truncated from the N terminus, aIIbb3 CHO K1 cells adhered to 0.5% QAGDVC (E) and
0.5% AGDVC (F) SAMs, but failed to adhere to 0.5% GDVC SAMs (G). When KQAGDVC was truncated from the C terminus, aIIbb3 CHO K1 cells adhered to
0.5% KQAGDC (H) SAMs, but failed to adhere to 0.5% KQAGC SAMs (I). Scale bars are 300 mm.adhered and spread efficiently on model substrates presenting
either the GRGDSC or HHLGGAKQAGDVC peptides and were
similar to cells that were adherent on Fbg-coated substrates.
The well-developed cytoskeletal structure in cells—including
the distributed focal adhesions and clear actin stress fila-
ments—suggests that each of the peptide ligands has sufficient
affinity for the platelet receptor to mediate biologically relevant
adhesion. Furthermore, control experiments establish that the
adhesion of cells is mediated primarily by the immobilized
ligand, because monolayers presenting no peptide or scram-
bled forms of the peptide failed to support cell adhesion. Inhibi-
tion experiments reveal that the two peptides bind competitively
to the receptor, because either peptide in soluble form showed
a dose-dependent inhibition of the attachment of cells to mono-
layers presenting either peptide. This result, as discussed
below, provides biochemical data that are consistent with
a recent X-ray structure that makes a strong argument that the
RGD and g peptides bind to a common site on aIIbb3. Taken
together, these results show that GRGDS and HHLGGAK
QAGDV bind to a common site in aIIbb3 and can independently
mediate efficient cell adhesion, spreading, and cytoskeletal
organization.
Structural Data of aIIbb3 Bound to Fbg Peptides
Is Consistent with Cell Adhesion Data
The recent report by Springer and co-workers described crystal
structures of the complexes formed between aIIbb3 and either
the HHLGGAKQAGDV or HHLGGAKQRGDV peptides (Springer
et al., 2008). The structures revealed that the binding site for the
g peptide overlaps that for the RGD peptide. Therefore, these
structural data provide strong evidence that the peptides share
a common binding site and, as stated above, appear to settle
this open question by ruling out separate, and potentially syner-
gistic, binding sites for the two peptides. Our experimental
finding that the peptides can competitively block the adhesion
of cells is consistent with this report, and, together, the two
studies provide structural and biochemical evidence that the
peptides bind a common site in aIIbb3.Chemistry & Biology 16, 990–10A second question that has been debated and still remains
open concerns the minimal peptide motif within the g peptide
that is sufficient for high-affinity binding to the receptor. We
approached this question by comparing cell attachment to
monolayers presenting different fragments of the g peptide
and we found that the AGD peptide alone efficiently mediates
cell adhesion and spreading. Furthermore, inhibition experi-
ments revealed that both the RGD and AGD peptides, at similar
concentrations, prevented cell attachment to a monolayer pre-
senting the RGD adhesion ligand, suggesting that the two
peptides have comparable affinity for the aIIbb3 integrin. This
result was surprising, because the Arg to Ala substitution
involves dramatic changes in charge and size of the residue
side chain. Other reports that are inconsistent with our findings
include the failure of an AGDV peptide to inhibit Fbg binding to
activated platelets (Plow et al., 1985). This study used soluble
peptides to compete for binding of radiolabeled Fbg to platelets,
but because platelets have other cell surface receptors that bind
to RGD—including avb3 and a5b1 (Kunicki, 1989)—these integ-
rins can mediate Fbg binding even in the presence of platelet
receptor antagonists (Humphries et al., 2006). RGD peptides,
in contrast, are efficient inhibitors of Fbg binding to platelets
because they block multiple integrins. AGD peptides, on the
other hand, can only block Fbg binding to integrin aIIbb3. We
also suggest that valency of the fibrinogen protein—which is
a dimer having both RGD and AGD motifs—is important for effi-
cient aggregation of platelets and that fibrinogen mutants that
delete either of these functions can have an impaired ability to
mediate aggregation.
Other published results are consistent, but not affirmative, of
our finding that AGD is the minimal binding sequence in
HHLGGAKQAGDV. Mice homozygous for a modified g se-
quence that lacked the QAGDV sequence displayed highly
defective platelet aggregation. The Fbg variant that included
this mutation also failed to bind to aIIbb3 in solid-phase assays
(Holmba¨ck et al., 1996). However, we are unaware of a study
that has tested explicitly the ability of the AGD tripeptide to block
the interaction of the platelet g chain with the receptor.00, September 25, 2009 ª2009 Elsevier Ltd All rights reserved 995
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pretation that theminimal bindingmotif is KQAGD. A comparison
of the complexes formed on binding of either the KQAGD
peptide or the RGD peptide reveal that, in both cases, the Asp
side chain interacts with a Mg2+ metal-ion dependent adhesion
site (MIDAS), and the Gly residue resides in a cleft between the
a and b subunits. Hence, aIIbb3 has a strict requirement for
the glycine and aspartate residues in the ligand. In the complex
formed on binding RGD, the side chain of Arg lies along a cleft
and positions the guanidinium group for hydrogen bonding to
aIIb residue Asp 224 and to an aIIb backbone carbonyl. For
the KQAGD peptide, the methyl side chain of alanine is directed
toward the guanidinium-binding pocket but cannot reach the
pocket. Instead, the peptide ligand interacts with an extended
binding site on the integrin and has a turn in the backbone that
leads to insertion of the lysine side chain into the arginine-binding
pocket, so that the ammonium group participates in the same
hydrogen-bonding pattern as does the guanidinium group of
the RGD peptide. This structure suggests a requirement for
a basic residue in the peptide ligand but allows the basic residue
to be separated from the Gly-Asp dyad, provided the peptide
can adopt a conformation that positions the lysine side chain
in the guanidinium-binding pocket.
The crystal structure does not provide information on the ener-
getic contribution made by the lysine residue within KQAGD to
the binding affinity of the peptide for the receptor. To address
this point, we compared cell adhesion to monolayers presenting
Ac-GAKQAGDVC, Ac-GASQAGDVC, GRGDSC, and AGDVC
and found that all ligands supported cell adhesion without signif-
icant differences (data not shown). Hence, the lysine appears to
not provide a strong contribution to the binding energy, at least
not for the densities of peptide used in our experiments. We
are not aware of any biochemical reports that address the impor-
tance of K406 in Fbg for binding to aIIbb3. A report by Hantgan
and co-workers addressed the binding of aIIbb3 with the disinte-
grin echistatin and used sedimentation velocity and fluores-
cence anisotropy assays to suggest that the Arg residue in
RGD accounted for only 20% of the binding energy between
the peptide ligand and aIIbb3—that is, an echistatin analog
that substituted AGD for RGD retained 80% of the activity for
binding to aIIbb3 (Hantgan et al., 2006). Although the crystal
structure reveals a direct contact between the integrin and Lys
406, we do not know whether the apparently favorable
hydrogen-bonding interaction formed by K406 in HHLGGAK
QAGDV with aIIbb3 could be compensated by an energetic
penalty for the turn in the backbone to position the lysine side
chain.
Figure 5. Inhibition of aIIbb3 CHO K1 Cells on Model Substrates
Inhibition of aIIbb3 CHO K1 cells incubated with [cRGDFG] = 300 mM tomono-
layers presenting 0.5%GRGDSC (A), 0.5%HHLGGAKQAGDVC (B), and 0.5%
AGDVC (C). Suspended cells were treated with either soluble GRGDS (A),
soluble HHLGGAKQAGDV (C), or soluble AGDV (:) at concentrations from
1 pM to 100 mMand then allowed to adhere to themodel substrates. Cell adhe-
sion was quantized as normalized units relative to adhesion in the absence of
soluble peptides. The scrambled peptides GGRDGS (>), GHHLGGADQAGKV
(B), and GADGV (6) were used to examine selective inhibition. The standard
error for each data point is within the range of 3%–6%, which is smaller than
the feature size for the data points.Elsevier Ltd All rights reserved
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AGD peptide is sufficient, and comparable to RGD, for binding
the integrin and that a basic residue is not necessary for the
activity of HHLGGAKQAGDV. Because of the obvious similarity
of the AGD and RGD motifs, we used a peptide array to
compare the adhesion of cells to peptides having the XGD
sequence. We observed that three cell lines that lacked aIIbb3
demonstrated adhesion only on the RGD peptide, consistent
with the extensive literature on integrin specificity (Ginsberg
et al., 1990; Li et al., 2003). The aIIbb3 CHO K1 cells, in
contrast, showed efficient adhesion to peptides having a basic
residue in the first position (Arg and Lys) but also to those
having small hydrophobic residues in this position (including
Gly, Ala, and Val, and to a lesser extent, Leu and Ile). Further-
more, cells on this latter set of peptides were well spread,
had distributed focal adhesions and clear stress fibers, and ap-
peared indistinguishable from cells on RGD. The GD scaffold
was necessary for adhesion, as demonstrated by the lack of
adhesion of all cells used to 0.5% GGRDGSC. Previous reports
have discussed the importance of the GD scaffold in integrin
binding. For the integrin aIIbb3, Plow and co-workers found
that conservative mutations Gly to Ala and Asp to Glu in
GRGDSP peptides were >100-fold less potent in inhibiting
platelet aggregation (Plow et al., 1985). Lazarus and co-workers
made variants of the snake venom kistrin, wherein each residue
was substituted with Ala. They found that D51A variant was
Figure 6. Cell Adhesion Mediated by
Ac-GXGDSC
(A) aIIbb3 CHO K1 cells, CHO K1 cells, BHK 21
cells and HT 1080 cells were allowed to adhere
to arrays of 0.5% GXGDSC. Cell adhesion was
quantized as normalized units relative to adhesion
in the 0.5% Ac-GRGDSC spot. Cells did not
adhere to the spot presenting 0.5% GGRDGSC.
Error bars are omitted for clarity. Immunostaining
of peptides that mediated aIIbb3 CHO K1 cell
adhesion on the array.
(B–F) (B) 0.5% Ac-GRGDSC, (C) 0.5% Ac-
GGGDSC, (D) 0.5% Ac-GAGDSC, (E) 0.5%
Ac-GKGDSC, and (F) 0.5% Ac-GVGDSC. Focal
adhesions were visualized with an anti-vinculin
antibody (red), actin stress fibers were visualized
with AF 488 phalloidin (green), and nuclei were
visualized with Hoescht (blue). Scale bars are
50 mm.
(G) 5X4 SAM array used for this work.
>200-fold less potent in platelet aggre-
gation inhibition than was wild-type kis-
trin. The D51E mutant was >100-fold
less potent in platelet aggregation inhibi-
tion (Dennis et al., 1993). Hence, this
result reveals the expanded binding
specificity of aIIbb3 and is consistent
with the general understanding that this
receptor is promiscuous relative to other
integrins.
It is significant that the atypical integrin
ligands we identified above are present
in the C-terminal g chain of several species. Lamprey and Xen-
opus g chains contain an RGD sequence, whereas human, dog,
and mouse contain an AGD sequence. Rat and chicken g chains
contain a VGD sequence, whereas zebrafish and carp contain
IGD and LGD triads, respectively (Springer et al., 2008). This
pattern is consistent with the evolution of Fbg and aIIbb3 to
introduce residues in the first position that abrogate binding of
these peptides to the other integrin receptors that mediate
adhesion in tissue and the endothelial cells lining the luminal
vessel.
Our results are further significant in that they suggest a novel
class of aIIbb3 antagonists that may have increased specificity
for the platelet receptor. Several cyclic peptides found in snake
venoms have been characterized as potent antithrombotic
agents and operate by using either a RGD or KGD motif to
bind the integrin (Scarborough et al., 1993; Oshiwaka and
Terada, 1999). The cyclic peptide eptifibatide—which has a
homoarginine residue in the first position—was derived from
barbourin (Scarborough et al., 1991) and is now used in clinical
settings to prevent platelet aggregation. Eptifibatide has gained
widespread use, because it overcomes the immunogenicity and
clearance time problems faced by abciximab, a Fab fragment
used to inhibit platelet aggregation. Although eptifibatide does
not cause immune response and follows renal body clearance
(Scarborough, 1999), one of its secondary effects is prolonged
bleeding in patients (Curran and Keating, 2005). Eptifibatide
Chemistry & Biology 16, 990–1000, September 25, 2009 ª2009 Elsevier Ltd All rights reserved 997
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affinity, and it has been suggested that the peptide binds this
integrin at therapeutic concentrations, though the conse-
quences of this interaction are not yet well characterized (Lele
et al., 2001). In this respect, inhibitors that display a greater spec-
ificity for aIIbb3 relative to other integrins may be valuable. Our
results suggest that linear or cyclic peptides having the AGD
motif, or other hydrophobic residues in the first position, may
serve as highly selective inhibitors of platelet aggregation.
Current efforts in our laboratory are now investigating the design
of novel antiaggregation molecules using the XGD scaffold,
where X is a hydrophobic residue.
Self-Assembled Monolayers as Models
of the Extracellular Matrix
This work is also significant because it demonstrates the utility
of self-assembled monolayers as mimics of the extracellular
matrix. Studies of cell adhesion, and of the ligands and receptors
that mediate adhesion, remain challenging because of the diffi-
culties in controlling the activities of ligands that are tethered
to culture substrates. ‘‘Inert’’ monolayers that present oligo(ethy-
lene glycol) chains are effective platforms for the study of ligand-
mediated cell adhesion. Furthermore, the ability to chemically
control the composition of themonolayer—including the density,
site of attachment, and nature of the tether of the ligand—
together with the use of mass spectrometry to confirm the struc-
ture of the surface makes these ECM mimics broadly applicable
to studies of the interactions of cells with ECM. We are particu-
larly intrigued by the possibility of using arrays prepared from
hundreds of peptides to identify novel adhesion ligands (Derda
et al., 2007).
SIGNIFICANCE
The regulated adhesion of cells is important in homeostasis
and disease. Studies of adhesion and the identification of
the ligands and receptors that mediate adhesion often use
protein-coated substrates and are complicated by the diffi-
culty in controlling the activities, identities, and densities
of the ligands. The development of model substrates—and
of self-assembled monolayers of alkanethiolates on gold in
particular—now provides routes to prepare structurally
defined surfaces for controlling the ligand-receptor interac-
tions that mediate adhesion. The present work has applied
the monolayer substrates to identify the peptide ligands in
Fbg that interact with the platelet integrin. We find that
aIIbb3 CHO K1 cells attach, spread, and assemble cytoskel-
eton on monolayers presenting both the RGD and the
HHLGGAKQAGDVC ligands. Furthermore, inhibition experi-
ments reveal that these two ligands bind competitively to
the receptor, in agreement with a recent structural study.
Of greater significance, this work compared cell adhesion
to a peptide array and revealed that the platelet receptor
recognizes peptides of the form XGD, where X can either
be a basic or hydrophobic group. This relaxed specificity
for the receptor is unprecedented and suggests the design
of antagonists that better discriminate in binding to the
platelet receptor relative to other integrins and that may
lead to a new class of antithrombotic agents.998 Chemistry & Biology 16, 990–1000, September 25, 2009 ª2009 EEXPERIMENTAL PROCEDURES
Antibodies and Reagents
All reagents were used as received. All amino acids and peptide synthesis
reagents were purchased from Anaspec, with the exception of Fmoc-
Asp(WangLL)-ODmab resin, which was obtained from EMD Chemicals. Anti-
integrin antibody PAC-1 (anti-aIIbb3) was obtained from BD Biosciences.
Other anti-integrin antibodies, M-148 (anti-aIIb) and H-96 (anti-b3), were
purchased from Santa Cruz Biotechnology. Monoclonal anti-vinculin antibody
was obtained from Sigma. Texas Red goat anti-mouse IgG, AF 488 goat anti-
mouse IgG, AF 488 goat anti-rabbit IgG, and AF 488 phalloidin were obtained
from Invitrogen. DAPI (40,6-diamidino-2-phenylindole) was obtained from
Molecular Probes. Human Fbg was obtained from Sigma. FuGENE transfec-
tion reagent was purchased from Roche. F-12K cell culture medium was
purchased from ATCC. All other cell culturemedia and reagents were obtained
from GIBCO, with the exception of geneticin and zeocin, which were from
Invitrogen.
Peptide Synthesis
Linear peptides were synthesized manually following standard Fmoc peptide
synthesis protocols using Fmoc-Rink amide MBHA resin. The cyclic peptide
cRGDFG, where F is a D amino acid, was synthesized using standard Fmoc
peptide synthesis protocol using Fmoc-Asp(WangLL)-ODmab resin. The
Dmab group was cleaved using 2% hydrazine in DMF for 20 min, and the
peptide was cyclized by treatment with 3 equivalents of HOBt and DIC for
4 hr. All peptides were purified by reverse-phase HPLC using a C18 column
(Waters) and characterized with Matrix-Assisted Laser Desorption/Ionization
Time of Flight Mass Spectrometry (MALDI-TOF MS).
Preparation of Monolayers
Monolayers were prepared as described elsewhere (Houseman et al., 2003).
Glass coverslips were sonicated for 30 min in deionized ultrafiltered (DIUF)
water and for 30min in ethanol and then were dried under a stream of nitrogen.
Titanium (4 nm) and then gold (29 nm) were evaporated onto the coverslips
using an electron beam evaporator (Boc Edwards) at a rate of 0.05–0.10 nm/s
and at a pressure of 1 mTorr. The gold-coated coverslips were immersed in an
ethanolic solution of maleimide-terminated disulfide (1%) and tri(ethylene
glycol)-terminated disulfide (99%) overnight at room temperature. The total
disulfide concentration was 1 mM. The substrates were washed with DIUF
water and ethanol and then were dried under a stream of nitrogen.
cDNA Constructs, Transfection, and Cell Culture
Constructs for aIIb and b3 were a gift from Professor Joel Bennet. CHO K1,
BHK 21, and HT1080 cells were purchased from ATCC. All CHO cells were
cultured at 37C and 5% CO2 using F12K medium supplemented with 10%
FBS and pen/strep. Other cell lines were cultured in the same conditions using
medium suggested by ATCC. CHO K1 cells were transfected with aIIb and b3
cDNA with FuGENE following the supplier’s protocol. Transfected cells were
selected with 1 mg/mL zeocin and 1 mg/mL geneticin.
Cell Adhesion Assay
Cysteine-terminated peptides were immobilized onto maleimide-presenting
SAMs by immersing the chip in 1 mM peptide solution and incubating at
37C for 1 hr. Substrates were rinsed with DIUF water and ethanol and were
dried under a stream of nitrogen. aIIbb3 CHO K1 cells were detached from
culture plates with 1 mM EGTA/2 mM EDTA in PBS, were rinsed with serum-
free F-12K medium, were centrifuged, and were resuspended in serum-free
F-12K medium supplemented with cRGDFG (300 mM) and 13 penicillin/strep-
tomycin. After 15 min of incubation, cells (200,000/mL) were added to
substrates in 24-well culture plates. After 2 hr incubation at 37C and 5%
CO2, media was exchanged for F-12K medium supplemented with 10%
FBS, 13 penicillin/streptomycin, and cRGDFG (300 mM). After 2 hr, the
substrateswerewashed gentlywithwarmPBS, and adherent cells were imme-
diately fixed with 4% formaldehyde for 30 min, visualized with a 203 objective
of a Zeiss Axiovert 200 inverted microscope, and imaged. For cell adhesion
assays mediated by Ac-GXGDSC, aIIbb3 CHO K1 cells were incubated
on a 53 4 circle (1 mm diameter) array for 1 hr with serum-free F-12K medium
supplemented with cRGDFG (300 mM) and 13 penicillin/streptomycin,lsevier Ltd All rights reserved
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13 penicillin/streptomycin, and cRGDFG (300 mM). The substrates were
washed with warm PBS, and adherent cells were immediately fixed and
permeabilized with 4% formaldehyde and 0.5% Triton-X for 30min. Fixed cells
were stained with DAPI, visualized, and imaged with a 203 objective as
described. The number of adherent cells per field of view was counted using
Image J software. Cells were counted in at least three fields of view for each
circle, and each experiment was repeated 3 times. The degree of adhesion is
reported as a percentage of cells that adhere relative to control experiments
with the peptide Ac-GRGDSC.
Immunostaining
aIIbb3 CHO K1 cells were allowed to adhere and spread on substrates as
described above. Substrates were washed gently with PBS, and fixed and
permebealized as described above. Cells were stained with monoclonal
anti-vinculin IgG (1:1000) to visualize focal adhesions, phalloidin (1:500) to
visualize stress fibers, and DAPI (1:5000) to visualize the nucleus. Substrates
were rinsed thoroughly with PBS and mounted on microscope slides with
Aqua Poly/Mount (PolySciences Inc.). Substrates were visualized with a
1003 objective of a Zeiss Axiovert 200 inverted microscope and were imaged.
Cell Adhesion Inhibition Assay
Suspensions of aIIbb3 CHO K1 cells (100,000/mL) were incubated with
cRGDFG (300 mM) in serum-free F-12K medium with 1 mg/mL BSA and 13
penicillin/streptomycin for 15 min at 37C and 5% CO2. These suspensions
were then supplemented with soluble peptides at concentrations raging
from 1 pM to 100 mM and were further incubated for 15 min at 37C and 5%
CO2. Cells were then added to monolayers and incubated at 37
C and 5%
CO2 for 2 hr, and thenmedia was exchanged for F-12Kmedium supplemented
with 10% FBS and 13 penicillin/streptomycin. The substrates were further
incubated for 2 hr. The substrates were washed gently with warm PBS, and
adherent cells were immediately fixed and permebealized with 4% formalde-
hyde and 0.5% Triton-X for 30 min. Fixed cells were stained with DAPI, visual-
ized, and imagedwith a 203 objective, as described previously. The number of
adherent cells per field of viewwas counted using Image J. Cells were counted
in at least five adjacent fields for each substrate, and each experiment was
repeated 3 times. The degree of inhibition is reported as a percentage of cells
that adhere relative to control experiments in the absence of soluble peptide.
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